Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.52 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.52 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21084328 | 0.98 | GNAI3 (0.55) | GNAI3GNAO1GNAI1KDM4ELMNA | |
| SCHEMBL4914105 | 0.98 | GNAI3 (0.55) | GNAI3GNAO1GNAI1KDM4ELMNA | |
| SCHEMBL4915224 | 0.94 | GNAI3 (0.44) | GNAI3GNAO1GNAI1KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL29165064 | 0.92 | GNAI3 (0.47) | GNAI3GNAO1GNAI1KDM4ELMNA | |
| SCHEMBL9536785 | 0.88 | GNAI3 (0.44) | GNAI3GNAO1GNAI1KDM4ELMNA | |
| SCHEMBL13632361 | 0.88 | HSD17B10 (0.46) | GNAI3GNAO1GNAI1HSD17B10 | |
| SCHEMBL3947375 | 0.85 | DRD2 (0.44) | GNAI3GNAO1GNAI1GAAHSD17B10 | |
| SCHEMBL5574053 | 0.84 | HSD17B10 (0.47) | HTR1AHSD17B10KCNH2 | |
| SCHEMBL11259811 | 0.82 | DRD2 (0.40) | GNAI3GNAO1GNAI1HTR1AGAA | |
| SCHEMBL1043043 | 0.82 | GNAI3 (0.70) | GNAI3GNAO1GNAI1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015031381-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C | ENANTA PHARMACEUTICALS, INC. (US) | 2015-03-05 | — | — | WO | disclosed |
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| EP-1820799-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| EP-0277836-B1 | THIAZOLIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR USE | Sankyo Company Limited (JP) | 1993-06-02 | — | — | EP | disclosed |
| US-5104888-A | Anticholesterol or antidiabetic agents | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0207581-B1 | THIAZOLIDINE DERIVATIVES, THEIR PREPARATION AND USE | SANKYO COMPANY LIMITED (JP) | 1990-09-12 | — | — | EP | disclosed |
| US-4873255-A | REDUCE BLOOD GLUCOSE AND BLOOD LIPID LEVELS | SANKYO COMPANY LIMITED (JP) | 1989-10-10 | — | — | US | disclosed |
| EP-0277836-A1 | Thiazolidinone derivatives, their preparation and their use | Sankyo Company Limited (JP) | 1988-08-10 | — | — | EP | disclosed |
| EP-0207581-A2 | Thiazolidine derivatives, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1987-01-07 | — | — | EP | disclosed |
| US-4439606-A | ANTICHOLESTEROL, ANTILIPEMIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1984-03-27 | — | — | US | disclosed |
| EP-0094498-A2 | Antiatherosclerotic 1-piperazine derivatives | AMERICAN CYANAMID COMPANY (US) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | GABRA5, GABRA1, GABRB1 | GNAI3 1131/4885GNAO1 1472/4885GNAI1 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.